Nuvation Bio is trading at $6.12 (up 4.3%), extending its multi-day rebound. The surge follows: * The UK Medicines and Healthcare products Regulatory Agency (MHRA) validating partner Eisai's Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer. * This validation is a key regulatory milestone, expanding the drug's global footprint and reinforcing its role as a globally relevant ROS1-targeted therapy. * Analysts have also flagged the stock as potentially undervalued, with a consensus "Buy" rating.